<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37178170</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Presymptomatic grey matter alterations in ALS kindreds: a computational neuroimaging study of asymptomatic C9orf72 and SOD1 mutation carriers.</ArticleTitle><Pagination><StartPage>4235</StartPage><EndPage>4247</EndPage><MedlinePgn>4235-4247</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-023-11764-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The characterisation of presymptomatic disease-burden patterns in asymptomatic mutation carriers has a dual academic and clinical relevance. The understanding of disease propagation mechanisms is of considerable conceptual interests, and defining the optimal time of pharmacological intervention is essential for improved clinical trial outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a prospective, multimodal neuroimaging study, 22 asymptomatic C9orf72 GGGGCC hexanucleotide repeat carriers, 13 asymptomatic subjects with SOD1, and 54 "gene-negative" ALS kindreds were enrolled. Cortical and subcortical grey matter alterations were systematically appraised using volumetric, morphometric, vertex, and cortical thickness analyses. Using a Bayesian approach, the thalamus and amygdala were further parcellated into specific nuclei and the hippocampus was segmented into anatomically defined subfields.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Asymptomatic GGGGCC hexanucleotide repeat carriers in C9orf72 exhibited early subcortical changes with the preferential involvement of the pulvinar and mediodorsal regions of the thalamus, as well as the lateral aspect of the hippocampus. Volumetric approaches, morphometric methods, and vertex analyses were anatomically consistent in capturing focal subcortical changes in asymptomatic C9orf72 hexanucleotide repeat expansion carriers. SOD1 mutation carriers did not exhibit significant subcortical grey matter alterations. In our study, none of the two asymptomatic cohorts exhibited cortical grey matter alterations on either cortical thickness or morphometric analyses.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The presymptomatic radiological signature of C9orf72 is associated with selective thalamic and focal hippocampal degeneration which may be readily detectable before cortical grey matter changes ensue. Our findings confirm selective subcortical grey matter involvement early in the course of C9orf72-associated neurodegeneration.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Bede</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0492-4772</Identifier><AffiliationInfo><Affiliation>Computational Neuroimaging Group (CNG), School of Medicine, Trinity College Dublin, Dublin, D02 RS90, Ireland. bedep@tcd.ie.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, St James's Hospital, Dublin, Ireland. bedep@tcd.ie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lul&#xe9;</LastName><ForeName>Doroth&#xe9;e</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Hans-Peter</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Ee Ling</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Computational Neuroimaging Group (CNG), School of Medicine, Trinity College Dublin, Dublin, D02 RS90, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorst</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre of Neurodegenerative Diseases (DZNE), Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kassubek</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre of Neurodegenerative Diseases (DZNE), Ulm, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HRB EIA-2017-019</GrantID><Acronym>HRBI_</Acronym><Agency>Health Research Board</Agency><Country>Ireland</Country></Grant><Grant><GrantID>JPND-Cofund-2-2019-1</GrantID><Acronym>HRBI_</Acronym><Agency>Health Research Board</Agency><Country>Ireland</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066128" MajorTopicYN="N">Gray Matter</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Asymptomatic</Keyword><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">Magnetic resonance imaging (MRI)</Keyword><Keyword MajorTopicYN="N">Pharmaceutical trials</Keyword><Keyword MajorTopicYN="N">Presymptomatic</Keyword><Keyword MajorTopicYN="N">SOD1</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>14</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>13</Day><Hour>14</Hour><Minute>58</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37178170</ArticleId><ArticleId IdType="pmc">PMC10421803</ArticleId><ArticleId IdType="doi">10.1007/s00415-023-11764-5</ArticleId><ArticleId IdType="pii">10.1007/s00415-023-11764-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1&#x2013;2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C, Berry JD, McKenna-Yasek DM, et al. SOD1 suppression with adeno-associated virus and microRNA in familial ALS. N Engl J Med. 2020;383:151&#x2013;158. doi: 10.1056/NEJMoa2005056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2005056</ArticleId><ArticleId IdType="pubmed">32640133</ArticleId></ArticleIdList></Reference><Reference><Citation>Omer T, Finegan E, Hutchinson S, et al. Neuroimaging patterns along the ALS-FTD spectrum: a multiparametric imaging study. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:611&#x2013;623. doi: 10.1080/21678421.2017.1332077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1332077</ArticleId><ArticleId IdType="pubmed">28562080</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke T, Pinto-Grau M, Lonergan K, et al. A Cross-sectional population-based investigation into behavioral change in amyotrophic lateral sclerosis: subphenotypes, staging, cognitive predictors, and survival. Ann Clin Transl Neurol. 2017;4:305&#x2013;317. doi: 10.1002/acn3.407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.407</ArticleId><ArticleId IdType="pmc">PMC5420811</ArticleId><ArticleId IdType="pubmed">28491898</ArticleId></ArticleIdList></Reference><Reference><Citation>Finegan E, Chipika RH, Shing SLH, Hardiman O, Bede P. Primary lateral sclerosis: a distinct entity or part of the ALS spectrum? Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:133&#x2013;145. doi: 10.1080/21678421.2018.1550518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1550518</ArticleId><ArticleId IdType="pubmed">30654671</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke T, Elamin M, Bede P, et al. Discordant performance on the 'reading the mind in the eyes' test, based on disease onset in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:467&#x2013;472. doi: 10.1080/21678421.2016.1177088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1177088</ArticleId><ArticleId IdType="pubmed">27152765</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Ziemann U, Eisen A. Amyotrophic lateral sclerosis: origins traced to impaired balance between neural excitation and inhibition in the neonatal period. Muscle Nerve. 2019;60:232&#x2013;235. doi: 10.1002/mus.26617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26617</ArticleId><ArticleId IdType="pubmed">31233613</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertrand A, Wen J, Rinaldi D, et al. Early cognitive, structural, and microstructural changes in presymptomatic C9orf72 carriers younger than 40 years. JAMA Neurol. 2018;75:236&#x2013;245. doi: 10.1001/jamaneurol.2017.4266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.4266</ArticleId><ArticleId IdType="pmc">PMC5838615</ArticleId><ArticleId IdType="pubmed">29197216</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G, Bede P, El Mendili MM, et al. Presymptomatic spinal cord pathology in c9orf72 mutation carriers: a longitudinal neuroimaging study. Ann Neurol. 2019;86:158&#x2013;167. doi: 10.1002/ana.25520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25520</ArticleId><ArticleId IdType="pubmed">31177556</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirak S, Arechavala-Gomeza V, Guglieri M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet. 2011;378:595&#x2013;605. doi: 10.1016/S0140-6736(11)60756-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(11)60756-3</ArticleId><ArticleId IdType="pmc">PMC3156980</ArticleId><ArticleId IdType="pubmed">21784508</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74:637&#x2013;647. doi: 10.1002/ana.23982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23982</ArticleId><ArticleId IdType="pubmed">23907995</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell JR, Goemans N, Lowes LP, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016;79:257&#x2013;271. doi: 10.1002/ana.24555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24555</ArticleId><ArticleId IdType="pmc">PMC5064753</ArticleId><ArticleId IdType="pubmed">26573217</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE, Sias AC, Mandelli ML, et al. Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. Neuroimage Clin. 2017;14:286&#x2013;297. doi: 10.1016/j.nicl.2016.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2016.12.006</ArticleId><ArticleId IdType="pmc">PMC5349617</ArticleId><ArticleId IdType="pubmed">28337409</ArticleId></ArticleIdList></Reference><Reference><Citation>Walhout R, Schmidt R, Westeneng HJ, et al. Brain morphologic changes in asymptomatic C9orf72 repeat expansion carriers. Neurology. 2015;85:1780&#x2013;1788. doi: 10.1212/WNL.0000000000002135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002135</ArticleId><ArticleId IdType="pubmed">26497991</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Blanc G, Jett&#xe9; Pomerleau V, McCarthy J, et al. Faster cortical thinning and surface area loss in presymptomatic and symptomatic C9orf72 repeat expansion adult carriers. Ann Neurol. 2020;2:2.</Citation><ArticleIdList><ArticleId IdType="pubmed">32285980</ArticleId></ArticleIdList></Reference><Reference><Citation>Papma JM, Jiskoot LC, Panman JL, et al. Cognition and gray and white matter characteristics of presymptomatic C9orf72 repeat expansion. Neurology. 2017;89:1256&#x2013;1264. doi: 10.1212/WNL.0000000000004393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004393</ArticleId><ArticleId IdType="pubmed">28855404</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; DE, M&#xfc;ller HP, Finsel J, et al. Deficits in verbal fluency in presymptomatic C9orf72 mutation gene carriers-a developmental disorder. J Neurol Neurosurg Psychiatry. 2020;91:1195&#x2013;1200. doi: 10.1136/jnnp-2020-323671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323671</ArticleId><ArticleId IdType="pmc">PMC7569387</ArticleId><ArticleId IdType="pubmed">32855285</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen J, Zhang H, Alexander DC, et al. Neurite density is reduced in the presymptomatic phase of C9orf72 disease. J Neurol Neurosurg Psychiatry. 2019;90:387&#x2013;394. doi: 10.1136/jnnp-2018-318994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318994</ArticleId><ArticleId IdType="pubmed">30355607</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vocht J, Blommaert J, Devrome M, et al. Use of multimodal imaging and clinical biomarkers in presymptomatic carriers of C9orf72 repeat expansion. JAMA Neurol. 2020;77:1&#x2013;10. doi: 10.1001/jamaneurol.2020.1087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1087</ArticleId><ArticleId IdType="pmc">PMC7417970</ArticleId><ArticleId IdType="pubmed">32421156</ArticleId></ArticleIdList></Reference><Reference><Citation>Babi&#x107; Leko M, &#x17d;upunski V, Kirincich J, et al. Molecular mechanisms of neurodegeneration related to C9orf72 hexanucleotide repeat expansion. Behav Neurol. 2019;2019:2909168. doi: 10.1155/2019/2909168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/2909168</ArticleId><ArticleId IdType="pmc">PMC6350563</ArticleId><ArticleId IdType="pubmed">30774737</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Isaacs AM. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol. 2018;14:544&#x2013;558. doi: 10.1038/s41582-018-0047-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0047-2</ArticleId><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng MC, Ho JT, Ho SL, et al. Abnormal diffusion tensor in nonsymptomatic familial amyotrophic lateral sclerosis with a causative superoxide dismutase 1 mutation. J Magn Reson Imaging. 2008;27:8&#x2013;13. doi: 10.1002/jmri.21217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmri.21217</ArticleId><ArticleId IdType="pubmed">18022844</ArticleId></ArticleIdList></Reference><Reference><Citation>Carew JD, Nair G, Andersen PM, et al. Presymptomatic spinal cord neurometabolic findings in SOD1-positive people at risk for familial ALS. Neurology. 2011;77:1370&#x2013;1375. doi: 10.1212/WNL.0b013e318231526a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318231526a</ArticleId><ArticleId IdType="pmc">PMC3182757</ArticleId><ArticleId IdType="pubmed">21940617</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Hammers A, Al-Chalabi A, et al. Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]flumazenil PET. Brain. 2005;128:1323&#x2013;1329. doi: 10.1093/brain/awh509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh509</ArticleId><ArticleId IdType="pubmed">15843422</ArticleId></ArticleIdList></Reference><Reference><Citation>Panman JL, Jiskoot LC, Bouts M, et al. Gray and white matter changes in presymptomatic genetic frontotemporal dementia: a longitudinal MRI study. Neurobiol Aging. 2019;76:115&#x2013;124. doi: 10.1016/j.neurobiolaging.2018.12.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.12.017</ArticleId><ArticleId IdType="pubmed">30711674</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Nicholas JM, Cash DM, et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol. 2015;14:253&#x2013;262. doi: 10.1016/S1474-4422(14)70324-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70324-2</ArticleId><ArticleId IdType="pmc">PMC6742501</ArticleId><ArticleId IdType="pubmed">25662776</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney NT, Ong E, Goh SM, et al. Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimers Dement. 2020;16:49&#x2013;59. doi: 10.1016/j.jalz.2019.08.196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.08.196</ArticleId><ArticleId IdType="pmc">PMC6988137</ArticleId><ArticleId IdType="pubmed">31784375</ArticleId></ArticleIdList></Reference><Reference><Citation>Cash DM, Bocchetta M, Thomas DL, et al. Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiol Aging. 2018;62:191&#x2013;196. doi: 10.1016/j.neurobiolaging.2017.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.10.008</ArticleId><ArticleId IdType="pmc">PMC5759893</ArticleId><ArticleId IdType="pubmed">29172163</ArticleId></ArticleIdList></Reference><Reference><Citation>Diehl-Schmid J, Licata A, Goldhardt O, et al. FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations. Transl Psychiatry. 2019;9:54. doi: 10.1038/s41398-019-0381-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-019-0381-1</ArticleId><ArticleId IdType="pmc">PMC6355852</ArticleId><ArticleId IdType="pubmed">30705258</ArticleId></ArticleIdList></Reference><Reference><Citation>Malpetti M, Holland N, Jones PS, et al. Synaptic density in carriers of C9orf72 mutations: a [(11) C]UCB-J PET study. Ann Clin Transl Neurol. 2021;8:1515&#x2013;1523. doi: 10.1002/acn3.51407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51407</ArticleId><ArticleId IdType="pmc">PMC8283163</ArticleId><ArticleId IdType="pubmed">34133849</ArticleId></ArticleIdList></Reference><Reference><Citation>van Veenhuijzen K, Westeneng HJ, Tan HHG, et al. Longitudinal effects of asymptomatic C9orf72 carriership on brain morphology. Ann Neurol. 2022;2:2.</Citation><ArticleIdList><ArticleId IdType="pubmed">36511398</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoukry RS, Waugh R, Bartlett D, Raitcheva D, Floeter MK. Longitudinal changes in resting state networks in early presymptomatic carriers of C9orf72 expansions. Neuroimage Clin. 2020;28:102354. doi: 10.1016/j.nicl.2020.102354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2020.102354</ArticleId><ArticleId IdType="pmc">PMC7406915</ArticleId><ArticleId IdType="pubmed">32769055</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonelli RM, Cummings JL. Frontal-subcortical circuitry and behavior. Dialog Clin Neurosci. 2007;9:141&#x2013;151. doi: 10.31887/DCNS.2007.9.2/rbonelli.</Citation><ArticleIdList><ArticleId IdType="doi">10.31887/DCNS.2007.9.2/rbonelli</ArticleId><ArticleId IdType="pmc">PMC3181854</ArticleId><ArticleId IdType="pubmed">17726913</ArticleId></ArticleIdList></Reference><Reference><Citation>Lule D, Diekmann V, Muller HP, Kassubek J, Ludolph AC, Birbaumer N. Neuroimaging of multimodal sensory stimulation in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2010;81:899&#x2013;906. doi: 10.1136/jnnp.2009.192260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.192260</ArticleId><ArticleId IdType="pubmed">20543183</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna MC, Lope J, Bede P, Tan EL. Thalamic pathology in frontotemporal dementia: predilection for specific nuclei, phenotype-specific signatures, clinical correlates, and practical relevance. Brain Behav. 2023;2:e2881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9927864</ArticleId><ArticleId IdType="pubmed">36609810</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna MC, Li Hi Shing S, Murad A, et al. Focal thalamus pathology in frontotemporal dementia: phenotype-associated thalamic profiles. J Neurol Sci. 2022;436:120221. doi: 10.1016/j.jns.2022.120221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2022.120221</ArticleId><ArticleId IdType="pubmed">35279595</ArticleId></ArticleIdList></Reference><Reference><Citation>Chipika RH, Christidi F, Finegan E, et al. Amygdala pathology in amyotrophic lateral sclerosis and primary lateral sclerosis. J Neurol Sci. 2020;417:117039. doi: 10.1016/j.jns.2020.117039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117039</ArticleId><ArticleId IdType="pubmed">32713609</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkhardt EH, van Elst LT, Ludolph AC, Kassubek J. Amygdala size in amyotrophic lateral sclerosis without dementia: an in vivo study using MRI volumetry. BMC Neurol. 2006;6:48. doi: 10.1186/1471-2377-6-48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-6-48</ArticleId><ArticleId IdType="pmc">PMC1764753</ArticleId><ArticleId IdType="pubmed">17189609</ArticleId></ArticleIdList></Reference><Reference><Citation>Chipika RH, Siah WF, Shing SLH, et al. MRI data confirm the selective involvement of thalamic and amygdalar nuclei in amyotrophic lateral sclerosis and primary lateral sclerosis. Data Brief. 2020;2:106246. doi: 10.1016/j.dib.2020.106246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dib.2020.106246</ArticleId><ArticleId IdType="pmc">PMC7481815</ArticleId><ArticleId IdType="pubmed">32944601</ArticleId></ArticleIdList></Reference><Reference><Citation>Christidi F, Karavasilis E, Rentzos M, et al. Hippocampal pathology in amyotrophic lateral sclerosis: selective vulnerability of subfields and their associated projections. Neurobiol Aging. 2019;84:178&#x2013;188. doi: 10.1016/j.neurobiolaging.2019.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.07.019</ArticleId><ArticleId IdType="pubmed">31629116</ArticleId></ArticleIdList></Reference><Reference><Citation>Christidi F, Karavasilis E, Velonakis G, et al. The clinical and radiological spectrum of hippocampal pathology in amyotrophic lateral sclerosis. Front Neurol. 2018;9:523. doi: 10.3389/fneur.2018.00523.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00523</ArticleId><ArticleId IdType="pmc">PMC6037820</ArticleId><ArticleId IdType="pubmed">30018591</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassubek J, M&#xfc;ller HP, Del Tredici K, et al. Imaging the pathoanatomy of amyotrophic lateral sclerosis in vivo: targeting a propagation-based biological marker. J Neurol Neurosurg Psychiatry. 2018;89:374&#x2013;381. doi: 10.1136/jnnp-2017-316365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316365</ArticleId><ArticleId IdType="pmc">PMC5869447</ArticleId><ArticleId IdType="pubmed">29101254</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B. FreeSurfer. Neuroimage. 2012;62:774&#x2013;781. doi: 10.1016/j.neuroimage.2012.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2012.01.021</ArticleId><ArticleId IdType="pmc">PMC3685476</ArticleId><ArticleId IdType="pubmed">22248573</ArticleId></ArticleIdList></Reference><Reference><Citation>Iglesias JE, Insausti R, Lerma-Usabiaga G, et al. A probabilistic atlas of the human thalamic nuclei combining ex vivo MRI and histology. Neuroimage. 2018;183:314&#x2013;326. doi: 10.1016/j.neuroimage.2018.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2018.08.012</ArticleId><ArticleId IdType="pmc">PMC6215335</ArticleId><ArticleId IdType="pubmed">30121337</ArticleId></ArticleIdList></Reference><Reference><Citation>Saygin ZM, Kliemann D, Iglesias JE, et al. High-resolution magnetic resonance imaging reveals nuclei of the human amygdala: manual segmentation to automatic atlas. Neuroimage. 2017;155:370&#x2013;382. doi: 10.1016/j.neuroimage.2017.04.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2017.04.046</ArticleId><ArticleId IdType="pmc">PMC5557007</ArticleId><ArticleId IdType="pubmed">28479476</ArticleId></ArticleIdList></Reference><Reference><Citation>Iglesias JE, Augustinack JC, Nguyen K, et al. A computational atlas of the hippocampal formation using ex vivo, ultra-high resolution MRI: application to adaptive segmentation of in vivo MRI. Neuroimage. 2015;115:117&#x2013;137. doi: 10.1016/j.neuroimage.2015.04.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2015.04.042</ArticleId><ArticleId IdType="pmc">PMC4461537</ArticleId><ArticleId IdType="pubmed">25936807</ArticleId></ArticleIdList></Reference><Reference><Citation>Machts J, Loewe K, Kaufmann J, et al. Basal ganglia pathology in ALS is associated with neuropsychological deficits. Neurology. 2015;85:1301&#x2013;1309. doi: 10.1212/WNL.0000000000002017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002017</ArticleId><ArticleId IdType="pubmed">26385880</ArticleId></ArticleIdList></Reference><Reference><Citation>Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage. 2011;56:907&#x2013;922. doi: 10.1016/j.neuroimage.2011.02.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2011.02.046</ArticleId><ArticleId IdType="pmc">PMC3417233</ArticleId><ArticleId IdType="pubmed">21352927</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler AM, Ridgway GR, Webster MA, Smith SM, Nichols TE. Permutation inference for the general linear model. Neuroimage. 2014;92:381&#x2013;397. doi: 10.1016/j.neuroimage.2014.01.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2014.01.060</ArticleId><ArticleId IdType="pmc">PMC4010955</ArticleId><ArticleId IdType="pubmed">24530839</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp. 2002;15:1&#x2013;25. doi: 10.1002/hbm.1058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.1058</ArticleId><ArticleId IdType="pmc">PMC6871862</ArticleId><ArticleId IdType="pubmed">11747097</ArticleId></ArticleIdList></Reference><Reference><Citation>Frazier JA, Chiu S, Breeze JL, et al. Structural brain magnetic resonance imaging of limbic and thalamic volumes in pediatric bipolar disorder. Am J Psychiatry. 2005;162:1256&#x2013;1265. doi: 10.1176/appi.ajp.162.7.1256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.162.7.1256</ArticleId><ArticleId IdType="pubmed">15994707</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Segonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968&#x2013;980. doi: 10.1016/j.neuroimage.2006.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2006.01.021</ArticleId><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Smith S, Jenkinson M, et al. Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia. Brain. 2007;130:2375&#x2013;2386. doi: 10.1093/brain/awm184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm184</ArticleId><ArticleId IdType="pubmed">17698497</ArticleId></ArticleIdList></Reference><Reference><Citation>Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage. 2001;14:21&#x2013;36. doi: 10.1006/nimg.2001.0786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nimg.2001.0786</ArticleId><ArticleId IdType="pubmed">11525331</ArticleId></ArticleIdList></Reference><Reference><Citation>Proudfoot M, Bede P, Turner MR. Imaging cerebral activity in amyotrophic lateral sclerosis. Front Neurol. 2018;9:1148. doi: 10.3389/fneur.2018.01148.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01148</ArticleId><ArticleId IdType="pmc">PMC6332509</ArticleId><ArticleId IdType="pubmed">30671016</ArticleId></ArticleIdList></Reference><Reference><Citation>Premi E, Calhoun VD, Diano M, et al. The inner fluctuations of the brain in presymptomatic frontotemporal dementia: the chronnectome fingerprint. Neuroimage. 2019;189:645&#x2013;654. doi: 10.1016/j.neuroimage.2019.01.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2019.01.080</ArticleId><ArticleId IdType="pmc">PMC6669888</ArticleId><ArticleId IdType="pubmed">30716457</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Laere K, Vanhee A, Verschueren J, et al. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014;71:553&#x2013;561. doi: 10.1001/jamaneurol.2014.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.62</ArticleId><ArticleId IdType="pubmed">24615479</ArticleId></ArticleIdList></Reference><Reference><Citation>Cistaro A, Pagani M, Montuschi A, et al. The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. Eur J Nucl Med Mol Imaging. 2014;2:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8957062</ArticleId><ArticleId IdType="pubmed">24445987</ArticleId></ArticleIdList></Reference><Reference><Citation>Christidi F, Karavasilis E, Argyropoulos GD, et al. Neurometabolic alterations in motor neuron disease: insights from magnetic resonance spectroscopy. J Integr Neurosci. 2022;21:87. doi: 10.31083/j.jin2103087.</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.jin2103087</ArticleId><ArticleId IdType="pubmed">35633168</ArticleId></ArticleIdList></Reference><Reference><Citation>Popuri K, Dowds E, Beg MF, et al. Gray matter changes in asymptomatic C9orf72 and GRN mutation carriers. Neuroimage Clin. 2018;18:591&#x2013;598. doi: 10.1016/j.nicl.2018.02.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2018.02.017</ArticleId><ArticleId IdType="pmc">PMC5964622</ArticleId><ArticleId IdType="pubmed">29845007</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Callaghan C, Bertoux M, Hornberger M. Beyond and below the cortex: the contribution of striatal dysfunction to cognition and behaviour in neurodegeneration. J Neurol Neurosurg Psychiatry. 2013;2:2.</Citation><ArticleIdList><ArticleId IdType="pubmed">23833269</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocchetta M, Iglesias JE, Neason M, Cash DM, Warren JD, Rohrer JD. Thalamic nuclei in frontotemporal dementia: Mediodorsal nucleus involvement is universal but pulvinar atrophy is unique to C9orf72. Hum Brain Mapp. 2020;41:1006&#x2013;1016. doi: 10.1002/hbm.24856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.24856</ArticleId><ArticleId IdType="pmc">PMC7267940</ArticleId><ArticleId IdType="pubmed">31696638</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE, Khazenzon AM, Trujillo AJ, et al. Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Brain. 2014;137:3047&#x2013;3060. doi: 10.1093/brain/awu248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu248</ArticleId><ArticleId IdType="pmc">PMC4208465</ArticleId><ArticleId IdType="pubmed">25273996</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruffaerts R, Gors D, B&#xe1;rcenas Gallardo A, et al. Hierarchical spectral clustering reveals brain size and shape changes in asymptomatic carriers of C9orf72. Brain Commun. 2022;4:182. doi: 10.1093/braincomms/fcac182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcac182</ArticleId><ArticleId IdType="pmc">PMC9311825</ArticleId><ArticleId IdType="pubmed">35898720</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Hi Shing S, McKenna MC, Siah WF, Chipika RH, Hardiman O, Bede P. The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development. Brain Imaging Behav. 2021;2:2.</Citation><ArticleIdList><ArticleId IdType="pubmed">33398779</ArticleId></ArticleIdList></Reference><Reference><Citation>Floeter MK, Bageac D, Danielian LE, Braun LE, Traynor BJ, Kwan JY. Longitudinal imaging in C9orf72 mutation carriers: Relationship to phenotype. Neuroimage Clin. 2016;12:1035&#x2013;1043. doi: 10.1016/j.nicl.2016.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2016.10.014</ArticleId><ArticleId IdType="pmc">PMC5153604</ArticleId><ArticleId IdType="pubmed">27995069</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, Ferraro PM, Riva N, et al. Structural and functional brain signatures of C9orf72 in motor neuron disease. Neurobiol Aging. 2017;57:206&#x2013;219. doi: 10.1016/j.neurobiolaging.2017.05.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.05.024</ArticleId><ArticleId IdType="pubmed">28666709</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan CT, Russ J, Wood EM, et al. C9orf72 promoter hypermethylation is neuroprotective: neuroimaging and neuropathologic evidence. Neurology. 2015;84:1622&#x2013;1630. doi: 10.1212/WNL.0000000000001495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001495</ArticleId><ArticleId IdType="pmc">PMC4409587</ArticleId><ArticleId IdType="pubmed">25795648</ArticleId></ArticleIdList></Reference><Reference><Citation>Chipika RH, Finegan E, Li Hi Shing S, et al. Switchboard malfunction in motor neuron diseases: Selective pathology of thalamic nuclei in amyotrophic lateral sclerosis and primary lateral sclerosis. Neuroimage Clin. 2020;27:102300. doi: 10.1016/j.nicl.2020.102300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2020.102300</ArticleId><ArticleId IdType="pmc">PMC7303672</ArticleId><ArticleId IdType="pubmed">32554322</ArticleId></ArticleIdList></Reference><Reference><Citation>Chipika RH, Mulkerrin G, Murad A, Lope J, Hardiman O, Bede P. Alterations in somatosensory, visual and auditory pathways in amyotrophic lateral sclerosis: an under-recognised facet of ALS. J Integr Neurosci. 2022;21:88. doi: 10.31083/j.jin2103088.</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.jin2103088</ArticleId><ArticleId IdType="pubmed">35633169</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Elamin M, Byrne S, et al. Basal ganglia involvement in amyotrophic lateral sclerosis. Neurology. 2013;81:2107&#x2013;2115. doi: 10.1212/01.wnl.0000437313.80913.2c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000437313.80913.2c</ArticleId><ArticleId IdType="pubmed">24212388</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Chipika RH, Christidi F, et al. Genotype-associated cerebellar profiles in ALS: focal cerebellar pathology and cerebro-cerebellar connectivity alterations. J Neurol Neurosurg Psychiatry. 2021;92:1197&#x2013;1205. doi: 10.1136/jnnp-2021-326854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-326854</ArticleId><ArticleId IdType="pmc">PMC8522463</ArticleId><ArticleId IdType="pubmed">34168085</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Walhout R, Straathof M, et al. Widespread structural brain involvement in ALS is not limited to the C9orf72 repeat expansion. J Neurol Neurosurg Psychiatry. 2016;87:1354&#x2013;1360. doi: 10.1136/jnnp-2016-313959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-313959</ArticleId><ArticleId IdType="pmc">PMC5136726</ArticleId><ArticleId IdType="pubmed">27756805</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Burgh HK, Westeneng HJ, Walhout R, et al. Multimodal longitudinal study of structural brain involvement in amyotrophic lateral sclerosis. Neurology. 2020;94:e2592&#x2013;e2604. doi: 10.1212/WNL.0000000000009498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009498</ArticleId><ArticleId IdType="pmc">PMC7455328</ArticleId><ArticleId IdType="pubmed">32414878</ArticleId></ArticleIdList></Reference><Reference><Citation>Finegan E, Li Hi Shing S, Chipika RH, et al. Widespread subcortical grey matter degeneration in primary lateral sclerosis: a multimodal imaging study with genetic profiling. Neuroimage Clin. 2019;24:102089. doi: 10.1016/j.nicl.2019.102089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2019.102089</ArticleId><ArticleId IdType="pmc">PMC6978214</ArticleId><ArticleId IdType="pubmed">31795059</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojsi F, Di Nardo F, Caiazzo G, et al. Hippocampal connectivity in amyotrophic lateral sclerosis (ALS): more than Papez circuit impairment. Brain Imaging Behav. 2020;2:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8413176</ArticleId><ArticleId IdType="pubmed">33095382</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosta F, Ferraro PM, Riva N, et al. Structural brain correlates of cognitive and behavioral impairment in MND. Hum Brain Mapp. 2016;37:1614&#x2013;1626. doi: 10.1002/hbm.23124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.23124</ArticleId><ArticleId IdType="pmc">PMC6867462</ArticleId><ArticleId IdType="pubmed">26833930</ArticleId></ArticleIdList></Reference><Reference><Citation>Feron M, Couillandre A, Mseddi E, et al. Extrapyramidal deficits in ALS: a combined biomechanical and neuroimaging study. J Neurol. 2018;265:2125&#x2013;2136. doi: 10.1007/s00415-018-8964-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8964-y</ArticleId><ArticleId IdType="pubmed">29995291</ArticleId></ArticleIdList></Reference><Reference><Citation>Abidi M, de Marco G, Grami F, et al. Neural correlates of motor imagery of gait in amyotrophic lateral sclerosis. J Magn Reson Imaging. 2021;53:223&#x2013;233. doi: 10.1002/jmri.27335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmri.27335</ArticleId><ArticleId IdType="pubmed">32896088</ArticleId></ArticleIdList></Reference><Reference><Citation>Abidi M, Pradat PF, Termoz N, Couillandre A, Bede P, de Marco G. Motor imagery in amyotrophic lateral Sclerosis: An fMRI study of postural control. Neuroimage Clin. 2022;35:103051. doi: 10.1016/j.nicl.2022.103051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2022.103051</ArticleId><ArticleId IdType="pmc">PMC9127212</ArticleId><ArticleId IdType="pubmed">35598461</ArticleId></ArticleIdList></Reference><Reference><Citation>Lule D, Ludolph AC, Ludolph AG. Neurodevelopmental and neurodegenerative diseases&#x2014;is there a pathophysiological link? Attention-deficit/hyperactivity disorder and amyotrophic lateral sclerosis as examples. Med Hypotheses. 2008;70:1133&#x2013;1138. doi: 10.1016/j.mehy.2007.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2007.11.002</ArticleId><ArticleId IdType="pubmed">18158219</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Siah WF, McKenna MC, Shing LH, S. Consideration of C9orf72-associated ALS-FTD as a neurodevelopmental disorder: insights from neuroimaging. J Neurol Neurosurg Psychiatry. 2020;2:2.</Citation><ArticleIdList><ArticleId IdType="pubmed">32855286</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsel J, Uttner I, V&#xe1;zquez Medrano CR, Ludolph AC, Lul&#xe9; D. Cognition in the course of ALS-a meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2022;2:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">35866707</ArticleId></ArticleIdList></Reference><Reference><Citation>Vertes RP, Hoover WB, Szigeti-Buck K, Leranth C. Nucleus reuniens of the midline thalamus: link between the medial prefrontal cortex and the hippocampus. Brain Res Bull. 2007;71:601&#x2013;609. doi: 10.1016/j.brainresbull.2006.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2006.12.002</ArticleId><ArticleId IdType="pmc">PMC4997812</ArticleId><ArticleId IdType="pubmed">17292803</ArticleId></ArticleIdList></Reference><Reference><Citation>Grollemund V, Pradat PF, Querin G, et al. Machine learning in amyotrophic lateral sclerosis: achievements, pitfalls, and future directions. Front Neurosci. 2019;13:135. doi: 10.3389/fnins.2019.00135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00135</ArticleId><ArticleId IdType="pmc">PMC6403867</ArticleId><ArticleId IdType="pubmed">30872992</ArticleId></ArticleIdList></Reference><Reference><Citation>Grollemund V, Le Chat G, Secchi-Buhour MS, et al. Manifold learning for amyotrophic lateral sclerosis functional loss assessment: development and validation of a prognosis model. J Neurol. 2021;268:825&#x2013;850. doi: 10.1007/s00415-020-10181-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10181-2</ArticleId><ArticleId IdType="pubmed">32886252</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Iyer PM, Finegan E, Omer T, Hardiman O. Virtual brain biopsies in amyotrophic lateral sclerosis: diagnostic classification based on in vivo pathological patterns. Neuroimage Clin. 2017;15:653&#x2013;658. doi: 10.1016/j.nicl.2017.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2017.06.010</ArticleId><ArticleId IdType="pmc">PMC5479963</ArticleId><ArticleId IdType="pubmed">28664036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Chang KM, Tan EL. Machine-learning in motor neuron diseases: prospects and pitfalls. Eur J Neurol. 2022;2:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9546434</ArticleId><ArticleId IdType="pubmed">35699315</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Murad A, Lope J, et al. Phenotypic categorisation of individual subjects with motor neuron disease based on radiological disease burden patterns: a machine-learning approach. J Neurol Sci. 2021;432:120079. doi: 10.1016/j.jns.2021.120079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.120079</ArticleId><ArticleId IdType="pubmed">34875472</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Murad A, Hardiman O. Pathological neural networks and artificial neural networks in ALS: diagnostic classification based on pathognomonic neuroimaging features. J Neurol. 2021;2:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9021106</ArticleId><ArticleId IdType="pubmed">34585269</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster C, Hardiman O, Bede P. Development of an automated MRI-based diagnostic protocol for amyotrophic lateral sclerosis using disease-specific pathognomonic features: a quantitative disease-state classification study. PLoS ONE. 2016;11:e0167331. doi: 10.1371/journal.pone.0167331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0167331</ArticleId><ArticleId IdType="pmc">PMC5132189</ArticleId><ArticleId IdType="pubmed">27907080</ArticleId></ArticleIdList></Reference><Reference><Citation>Behler A, M&#xfc;ller HP, Ludolph AC, Lul&#xe9; D, Kassubek J. A multivariate Bayesian classification algorithm for cerebral stage prediction by diffusion tensor imaging in amyotrophic lateral sclerosis. Neuroimage Clin. 2022;35:103094. doi: 10.1016/j.nicl.2022.103094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2022.103094</ArticleId><ArticleId IdType="pmc">PMC9253469</ArticleId><ArticleId IdType="pubmed">35772192</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster C, Hardiman O, Bede P. Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics. BMC Neurol. 2017;17:73. doi: 10.1186/s12883-017-0854-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-017-0854-x</ArticleId><ArticleId IdType="pmc">PMC5393027</ArticleId><ArticleId IdType="pubmed">28412941</ArticleId></ArticleIdList></Reference><Reference><Citation>Behler A, M&#xfc;ller HP, Del Tredici K, et al. Multimodal in vivo staging in amyotrophic lateral sclerosis using artificial intelligence. Ann Clin Transl Neurol. 2022;9:1069&#x2013;1079. doi: 10.1002/acn3.51601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51601</ArticleId><ArticleId IdType="pmc">PMC9268886</ArticleId><ArticleId IdType="pubmed">35684940</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan HHG, Westeneng HJ, Nitert AD, et al. MRI clustering reveals three ALS subtypes with unique neurodegeneration patterns. Ann Neurol. 2022;2:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9826424</ArticleId><ArticleId IdType="pubmed">36054734</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Murad A, Lope J, Hardiman O, Chang KM. Clusters of anatomical disease-burden patterns in ALS: a data-driven approach confirms radiological subtypes. J Neurol. 2022;45:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9294023</ArticleId><ArticleId IdType="pubmed">35333981</ArticleId></ArticleIdList></Reference><Reference><Citation>El Mendili MM, Querin G, Bede P, Pradat PF. Spinal cord imaging in amyotrophic lateral sclerosis: historical concepts-novel techniques. Front Neurol. 2019;10:350. doi: 10.3389/fneur.2019.00350.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00350</ArticleId><ArticleId IdType="pmc">PMC6474186</ArticleId><ArticleId IdType="pubmed">31031688</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Burgh HK, Schmidt R, Westeneng HJ, de Reus MA, van den Berg LH, van den Heuvel MP. Deep learning predictions of survival based on MRI in amyotrophic lateral sclerosis. Neuroimage Clin. 2017;13:361&#x2013;369. doi: 10.1016/j.nicl.2016.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2016.10.008</ArticleId><ArticleId IdType="pmc">PMC5219634</ArticleId><ArticleId IdType="pubmed">28070484</ArticleId></ArticleIdList></Reference><Reference><Citation>Chipika RH, Siah WF, McKenna MC, Li Hi Shing S, Hardiman O, Bede P. The presymptomatic phase of amyotrophic lateral sclerosis: are we merely scratching the surface? J Neurol. 2021;268:4607&#x2013;4629. doi: 10.1007/s00415-020-10289-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10289-5</ArticleId><ArticleId IdType="pubmed">33130950</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>